Screening for prostate cancer may not reduce mortality
نویسندگان
چکیده
منابع مشابه
Does PSA screening reduce prostate cancer mortality?
question whether the recent decline in age-standardized prostate cancer mortality rates in Quebec could be attributed to screening with the serum prostate-specific antigen (PSA) test. By comparing the change in the incidence rate of prostate cancer between 1989 and 1993 with the change in the prostate cancer mortality rate between 1995 and 1999 in 15 birth cohorts, and in 15 regions of Quebec, ...
متن کاملA Specific Screening Strategy to Reduce Prostate Cancer Mortality
Detection of prostate-specific antigen (PSA) as a screening strategy for prostate cancer is limited by the inability of the PSA test to differentiate between malignant cancer and benign hyperplasia. Here, we report the use of a cancer-specific promoter, inhibition of differentiation (Id1), to drive a dual-reporter diagnostic system (Ad5/3-Id1-SEAP-Id1-mCherry) for sensitive detection of prostat...
متن کاملPSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملEffects of Prostate Cancer Screening Mandates on Prostate Cancer Mortality
Health insurance mandates are playing a bigger role in today’s society as state representatives see increased benefits of certain health products. After being introduced to the general public, the PSA test has been shown to increase the finding of prostate cancer incidence and preventatively reduce prostate cancer mortality. Today, there are 33 states that have enacted legislation to require ei...
متن کاملPSA screening and prostate cancer mortality.
BACKGROUND Physicians have speculated that prostate-specific antigen (PSA) screening may be responsible for the reduction in prostate cancer mortality observed in the late 1 990s. In order to test this hypothesis, we assessed the relation between the change in prostate cancer incidence in the early 1990s, attributed largely to PSA screening, and the subsequent change in prostate cancer mortalit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2006
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.332.7533.72-g